| Diabetes Mellitus, Non-Insulin-Dependent

Inpefa vs Invokana

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.
Deep comparison between: Inpefa vs Invokana with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsInvokana has a higher rate of injection site reactions vs Inpefa based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Invokana but not Inpefa, including UnitedHealthcare
Sign up to reveal the full AI analysis
Inpefa
Invokana
At A Glance
Oral
Daily
SGLT1/SGLT2 inhibitor
Oral
Once daily
SGLT2 inhibitor
Indications
  • Heart failure
  • Diabetes Mellitus, Non-Insulin-Dependent
  • Chronic Kidney Diseases
  • Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Heart failure, Diabetes Mellitus, Non-Insulin-Dependent, Chronic Kidney Diseases 200 mg orally once daily, not more than one hour before the first meal; titrate after at least 2 weeks to 400 mg once daily as tolerated; down-titrate to 200 mg as necessary.
Diabetes Mellitus, Non-Insulin-Dependent (glycemic control) 100 mg orally once daily before the first meal of the day; may increase to 300 mg once daily in patients tolerating 100 mg with eGFR >= 60 mL/min/1.73 m2 who require additional glycemic control.
Cardiovascular risk reduction, Diabetic nephropathy 100 mg orally once daily.
Contraindications
  • History of serious hypersensitivity reaction to INPEFA
  • Serious hypersensitivity reaction to canagliflozin or any excipient, such as anaphylaxis or angioedema
Adverse Reactions
Most common (>=2%) Urinary tract infection, volume depletion, diarrhea, hypoglycemia, dizziness, genital mycotic infection
Serious Diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, hypoglycemia with insulin and insulin secretagogues, necrotizing fasciitis of the perineum, genital mycotic infections
Most common (>=2%) Urinary tract infections, increased urination, thirst, constipation, nausea, female genital mycotic infections, vulvovaginal pruritus, male genital mycotic infections
Serious Diabetic ketoacidosis, lower limb amputation, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, bone fracture
Postmarketing Ketoacidosis, acute kidney injury, anaphylaxis, angioedema, urosepsis and pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene)
Pharmacology
Sotagliflozin is a dual inhibitor of SGLT2 and SGLT1; SGLT2 inhibition reduces renal reabsorption of glucose and sodium (lowering cardiac pre- and afterload and downregulating sympathetic activity), while SGLT1 inhibition reduces intestinal absorption of glucose and sodium.
SGLT2 inhibitor; canagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and lowering the renal threshold for glucose, thereby increasing urinary glucose excretion; also blocks SGLT2-dependent sodium reabsorption, believed to increase tubuloglomerular feedback and reduce intraglomerular pressure.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inpefa
  • Covered on 5 commercial plans
  • PA (9/12) · Step Therapy (9/12) · Qty limit (10/12)
View full coverage details ›
Invokana
  • Covered on 5 commercial plans
  • PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Inpefa
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Invokana
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
View full coverage details ›
Humana
Inpefa
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
View full coverage details ›
Invokana
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
$10/fillfill
Inpefa Savings Card Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health Heart Failure Patient Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
InpefaView full Inpefa profile
InvokanaView full Invokana profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.